A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Teprasiran (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 07 Nov 2017 According to a Quark Pharmaceuticals media release, data will be presented at the EuroTIDES conference 2017.
- 04 Nov 2017 Results presented in a Quark Pharmaceuticals Media Release.
- 04 Nov 2017 According to a Quark Pharmaceuticals media release, data were presented at the American Society of Nephrology (ASN) / Kidney Week.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History